Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track HCM with free AI briefings, catalyst countdowns, and dilution alerts.

HCM · HUTCHMED (China) Ltd

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$1.4B Cash on Hand
CF+ Cash Runway
Follow HCM by email Get an email when HCM reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about HCM, unsubscribe in one click. Privacy

📣 What HCM Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Ranosidenib (HMPL-306) Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation Phase 3 · NCT07912398 Not yet recruiting
BTK Inhibitor HMPL-760 Relapsed/Refractory Diffuse Large B-Cell Lymphoma Phase 3 · NCT07409428 Recruiting
Salvage Chemotherapy Regimen Acute Myeloid Leukemia Phase 3 · NCT06387069 Recruiting
Sovleplenib (HMPL-523) Warm Antibody Autoimmune Hemolytic Anemia Phase 2/3 · NCT05535933 Active not recruiting
Savolitinib Non-small Cell Lung Cancer Phase 3 · NCT05009836 Active not recruiting
Sintilimab Advanced Endometrial Cancer Phase 3 · NCT06584032 Recruiting
Fanregratinib (HMPL-453) Advanced Intrahepatic Cholangiocarcinoma Phase 2/3 · NCT04353375 Recruiting
Camrelizumab Metastatic Pancreatic Cancer Phase 2/3 · NCT06361888 Recruiting
Surufatinib Metastatic Pancreatic Cancer Phase 2/3 · NCT06361888 Recruiting
Osimertinib Non-small Cell Lung Cancer Phase 3 · NCT05009836 Active not recruiting
Doxorubicin Advanced Endometrial Cancer Phase 3 · NCT06584032 Recruiting
Nab-paclitaxel Metastatic Pancreatic Cancer Phase 2/3 · NCT06361888 Recruiting
Pamiparib Ovarian Cancer Phase 1/2 · NCT05494580 Completed
Anti-EGFR Antibody-PI3K/PIKK Inhibitor… Solid Tumors, Adult Phase 1/2 · NCT07396584 Recruiting
Anti-HER2 Antibody-PI3K/PIKK Inhibitor… Solid Tumors, Adult Phase 1/2 · NCT07228247 Recruiting
Amdizalisib (HMPL-689) Relapsed/Refractory Lymphoma Phase 2 · NCT05713110 Completed

Also used in these trials (approved or third-party drugs, not HCM's own candidates): Rituximab, Paclitaxel, Fruquintinib, Axitinib, Tazemetostat, Tislelizumab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

HCM holds $1.4B in cash and short-term investments and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when HCM files for a raise →

👥 Who Owns HCM

Insiders 0.1% Institutions (67 holders) 2.5% Public and other holders 97.4%
HolderTypeShares% of sharesAs of
Wei-guo Su
CEO and CSO, Director · +208,004 options
Insider 237,063 0.03% 2026-03-16
Edith Shih
Director
Insider 100,000 0.01% 2026-03-10
Chig Fung Cheng
Acting CEO and CFO, Director · +56,464 options
Insider 56,693 0.01% 2026-03-11
Charles George Rupert Nixon
Group General Counsel · +15,089 options
Insider 41,763 0.00% 2026-03-31
Tony Shu Kam Mok
Former Director
Insider 27,341 0.00% 2026-03-10
Dan Eldar
Director
Insider 26,332 0.00% 2026-03-10
Renu Bhatia
Director
Insider 16,000 0.00% 2026-03-10
Lorenso Chiu
Deputy Chief Financial Officer · +14,039 options
Insider 8,475 0.00% 2026-03-18

Share count 872,327,620 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full HCM picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for HCM and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.